China Pharma
NPM · @PIPEWORX/MCP-CHINA-PHARMA · 2 COMPONENTS
China Pharma MCP — China-to-Western biotech licensing deals, from SEC filings.
Available components
Last scanned (4 hours ago)
Scores higher than 72% of npm servers
Category Health and Science
How this component scores in each security and reliability category. Every signal is checked automatically from public evidence about the published package, including repeated runs of it in an isolated sandbox, and we only credit what we can confirm. How we score → Why this is hard to score →
Supply Chain Security100
- No malware found by supply-chain analysis.Pass
- No known CVEs affecting this package version or its production dependencies.Pass
- No install/post-install scripts declared.Pass
- No production dependencies, so there is no dependency health to assess. View diagnostics → Pass
Provenance & Transparency97
- Source repository is publicly reachable at the declared URL. View diagnostics → Pass
- Cryptographically verified build provenance (signed, bound to pipeworx-io/mcp-china-pharma). View diagnostics → Pass
- Clear OSI-approved license (MIT).Pass
- Actively maintained (last published 5 days ago).Pass
- Disclosure check failed: no security disclosure policy was found in the source repository. See how to fix → Fail
Schema Quality & AI Usability62
- AI-judged instruction clarity (good).Pass
- Context-footprint check failed: tool/resource definitions use about 1196 tokens (~239/item across 5 items; 5 tools + 0 resources), over budget; trim descriptions and params. See how to fix → Fail
- Usage-examples check failed: none of the tools include examples. See how to fix → Fail
Stability & Change Management23
- Stability observed for 7 of 30 days with no destabilising changes; credit accrues until the full window elapses.Partial
Tool Coverage100
- 100% of tools have a non-trivial description (not blank, and not just the tool's name).Pass
- 100% of tool parameters carry a description.Pass
Tool Safety100
- No prompt-injection markers were found in the server instructions, tool names or descriptions we captured.Pass
- We read all 5 captured tool definition(s), and no name or description among them implies an irreversible operation.Pass
- An AI judge read all 6 captured unit(s) of tool text and found none that tries to manipulate the model reading it.Pass
Capabilities100
- Implements a supported MCP spec version (2025-11-25); the latest is 2026-07-28.Pass
Every change we have recorded for this component, newest first. Security-relevant changes are always shown. ▲ marks a change for the better, ▼ a change for the worse; unmarked changes are neutral.
- 5 Nov 26 +1
No change was recorded against any check on this day. Stability & Change Management went from 20 to 23. That category is still filling its 30-day observation window: 6 days of observed history at the previous scan, 7 at this one. The score rises as the window fills, whether or not the server changes.
- 3 Nov 26 +1
No change was recorded against any check on this day. Stability & Change Management went from 13 to 17. That category is still filling its 30-day observation window: 4 days of observed history at the previous scan, 5 at this one. The score rises as the window fills, whether or not the server changes.
- 1 Nov 26 +15
- Malware scan: unverified → pass ▲ security
- 31 Oct 26 −14
- Malware scan: pass → unverified ▼ security
- Package version: 0.3.0 → 0.3.1 functional
- 29 Oct 26 79
First indexed and scored.
Diagnostic detail from the automated scan of this channel: what the scanner observed at each step, so you can see exactly where a check passed or failed. It is informational only and never changes the trust score.
Captured 5 Nov 2026 · Analysed npm/@pipeworx/mcp-china-pharma@0.3.1
Provenance Verified
A signed build attestation was found and verified, binding this exact artifact to the source repository it claims to come from.
| Result | Verified |
|---|---|
| Ecosystem | npm |
| Reason | Verified |
| Discovered via | Registry attestation endpoint |
| Source repo | pipeworx-io/mcp-china-pharma |
| Certificate issuer | https://token.actions.githubusercontent.com |
| Certificate SAN | https://github.com/pipeworx-io/mcp-china-pharma/.github/workflows/publish.yml@refs/heads/main |
| Rekor log index | 3606776918 |
| Predicate type | SLSA build provenance https://slsa.dev/provenance/v1 |
| Subject digest | sha512:d365836f8198d7cfe4ee0de9f45e985059f40996ae85fffd432b6715db07a54885eefc3be52db4f46ad900fe6946126f8a075a22d3523617cfda627b4 |
Background: How many MCP packages publish verified provenance →
Dependencies 0 packages
| Packages resolved | 0 |
|---|---|
| Tree resolution | Complete |
Background: SBOMs and build attestations, explained →
The tools this component advertises to a client, with an estimated token cost for each. Expand a tool to see its parameters and schema. The per-tool counts are indicative and are not scored directly; the schema's total context footprint is one signal in Schema Quality & AI Usability. A tool's description is untrusted text the model reads on every call, which is what makes this list a security surface and not just an inventory: how tool poisoning works →
china_licensing_deals ~255
Biotech and pharmaceutical licensing deals involving China — a Chinese company out-licensing a drug to a Western partner, or a Western company licensing rights INTO Greater China. Returns the two companies, the drug or asset, the territory, the upfront payment, milestone totals and royalty terms, with the SEC filing they were announced in and its date. Answers "which Chinese biotechs signed out-licensing deals", "recent China pharma licensing deals", "who licensed rights in Greater China". Sourced from SEC 8-K announcements, so it covers any deal with a US-listed party. Filter by company, drug name or date window.
| Name | Type | Req | Description |
|---|---|---|---|
| limit | number | – | Maximum deals to return, 1-40 (default 10). |
| query | string | – | Optional extra term to narrow the search — a company ("Hengrui"), a drug ("VIZZ"), a modality ("ADC", "bispecific") or a therapy area ("oncology"). Combined with the deal and China terms, not replaci… |
| since | string | – | Earliest filing date (YYYY-MM-DD). Defaults to 90 days ago. |
| until | string | – | Latest filing date (YYYY-MM-DD). Defaults to today. |
No output schema declared.
No examples provided.
csrc_penalties ~227
Administrative penalty decisions (行政处罚决定书) from the CSRC — the China Securities Regulatory Commission, China's securities and capital-markets regulator — newest first, straight from csrc.gov.cn's own JSON feed. Each row carries the decision number (e.g. 〔2026〕42号), the publication date, the named parties from the decision's opening lines (listed companies, accounting firms, individuals sanctioned for disclosure fraud, insider trading, market manipulation), and the link to the full decision. Answers "recent CSRC enforcement actions", "中国证监会最近的行政处罚", "which companies did China's securities regulator penalize". This is securities-market enforcement, not drug regulation — for NMPA announcements use nmpa_updates.
| Name | Type | Req | Description |
|---|---|---|---|
| limit | number | – | Rows per page, 1-40 (default 15). |
| page | number | – | Page number, 1-based (default 1). Pages are newest-first. |
| since | string | – | Earliest publication date, YYYY-MM-DD. Omitted, the newest decisions are returned regardless of age. |
No output schema declared.
No examples provided.
nmpa_drug_approval ~154
One NMPA drug-approval record by id (the `id` field returned by nmpa_drug_approvals) or by name (a drug name, code, or company). 单个药品批准记录. Returns the same fields as nmpa_drug_approvals for the single best-matching filing, plus the filing headline as a summary. Use nmpa_drug_approvals to browse first if you do not already have an id.
| Name | Type | Req | Description |
|---|---|---|---|
| id | string | – | The `id` field from a prior nmpa_drug_approvals result. |
| name | string | – | A drug name, drug code, or company name to search for. |
No output schema declared.
No examples provided.
nmpa_drug_approvals ~347
NMPA (国家药监局) drug-APPROVAL events — a specific drug cleared for marketing, granted conditional approval, or given an expanded indication in China — as opposed to nmpa_updates, which is regulatory policy news. 批准 新药 创新药 获批上市 NMPA新药批准. Answers "latest NMPA drug approvals in China", "2026年8月NMPA批准的新药", "what new drugs did China approve this month", "recent Chinese biotech drug approvals". Sourced from HKEX (Hong Kong Exchange) disclosure filings: any Hong Kong-listed biotech announces an NMPA approval as a regulatory disclosure the same day, and that filing is public and structured. Returns the filing headline (which names the drug and often the indication), the company, the approval date, a best-effort category, and the filing PDF. Coverage is limited to HKEX-listed companies — see coverage_note in the response.
| Name | Type | Req | Description |
|---|---|---|---|
| limit | number | – | Maximum approvals to return, 1-40 (default 15). |
| month | string | – | A single month, "YYYY-MM" (e.g. "2026-08"). Takes priority over since/until. |
| query | string | – | Filter to filings whose headline or company name contains this text (drug name, code like "TY-9591", or company like "HUTCHMED"). |
| since | string | – | Earliest approval date, YYYY-MM-DD. Ignored if `month` is set. |
| until | string | – | Latest approval date, YYYY-MM-DD. Ignored if `month` is set. |
No output schema declared.
No examples provided.
nmpa_updates ~158
Official announcements from China's drug regulator, the NMPA (National Medical Products Administration) — regulatory policy changes, guidance documents, import rules, clinical-trial guideline updates and reform opinions, in English, straight from the regulator. Answers "latest NMPA regulatory updates", "what has China's drug regulator changed", "NMPA guidance on medical devices or cosmetics". Returns title, publication date and the announcement URL. NOTE: this is the announcements feed, NOT the drug-approval register — it does not list which drugs were approved.
| Name | Type | Req | Description |
|---|---|---|---|
| limit | number | – | Maximum announcements, 1-40 (default 15). |
| section | string | – | Limit to one section. Omitted, all four are merged and sorted newest first. |
No output schema declared.
No examples provided.
How do I install the China Pharma MCP server?
China Pharma runs locally as an npm package, launched with npx -y @pipeworx/mcp-china-pharma. Ready-made configuration for Claude, Cursor, VS Code, Codex and 5 more is on this page, copied from each client's own documentation.
npm · @pipeworx/mcp-china-pharma
claude mcp add pipeworx-io-china-pharma -- npx -y @pipeworx/mcp-china-pharma
What is the China Pharma MCP server?
China Pharma is an MCP server listed in the public MCP registry as io.github.pipeworx-io/china-pharma. China Pharma MCP, China-to-Western biotech licensing deals, from SEC filings. This page covers its npm package (@pipeworx/mcp-china-pharma).
Is the China Pharma MCP server safe to use?
China Pharma scores 82 out of 100 on VerifyMCP. We found no known CVEs affecting it as of 5 November 2026. It declares no install or post-install scripts. Its build provenance is signed and verified. That is a record of what we were able to check automatically, not an endorsement. The category breakdown on this page shows every signal behind the number, including the ones we could not confirm.
What tools does the China Pharma MCP server expose?
China Pharma exposes 5 tools: china_licensing_deals, nmpa_updates, nmpa_drug_approvals, csrc_penalties, nmpa_drug_approval. Their descriptions and schemas cost roughly 1,141 tokens of context every time the server is loaded.
Is the China Pharma MCP server still maintained?
China Pharma is still listed as active in the MCP registry. We last reached this channel on 5 November 2026. Those dates come from our own scans of the registry and the channel itself, not from anything the publisher announced.
What licence is the China Pharma MCP server under?
China Pharma declares the MIT licence, which is OSI-approved. That covers the source only, and says nothing about the cost of any service it calls.